688799.SHG Hunan Warrant Pharmaceutical Co. Ltd. A
- Market cap
- CNY 6.19B
- P/E
- 55.2x
- P/B
- 2.81x
- ROE
- 6.1%
- Dividend yield
- 1.02%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688799.SHG undervalued?
Graham number688799.SHG trades 162.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hunan Warrant Pharmaceutical Co. Ltd. A fundamental analysis
No fundamental analysis for Hunan Warrant Pharmaceutical Co. Ltd. A yet.
Hunan Warrant Pharmaceutical Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hunan Warrant Pharmaceutical Co. Ltd. A
Hunan Warrant Pharmaceutical Co.,Ltd manufactures and sells pharmaceutical products in China. It offers medicines in the areas of digestive, respiratory, anti-infective, diabetes, Hypertension, calcium supplementation cardiovascular, cerebrovascular, and other fields. The company also provides APIs and Intermediates. Hunan Warrant Pharmaceutical Co.,Ltd was founded in 2001 and is based in Changsha, China.
Full company profileHunan Warrant Pharmaceutical Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hunan Warrant Pharmaceutical Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 256M | 375M | 613M | 825M | 951M | 1.15B | 1.29B | 1.43B | 1.41B | 1.52B | 1.32B |
| Gross Profit | 117M | 220M | 427M | 578M | 688M | 827M | 871M | 921M | 865M | 1.52B | 747M |
| Operating Income | 19.2M | 56.0M | 104M | 128M | 161M | 182M | 196M | 237M | 162M | 245M | 165M |
| EBITDA | 30.0M | 92.7M | 128M | 154M | 194M | 214M | 244M | 291M | 231M | 314M | 154M |
| Net Income | 18.8M | 59.8M | 88.5M | 116M | 145M | 161M | 183M | 211M | 164M | 241M | 129M |
| EPS | 0.19 | 0.85 | 0.90 | 1.18 | 1.47 | 1.44 | 1.39 | 1.61 | 1.25 | 1.84 | 0.97 |
| Balance Sheet | |||||||||||
| Total Assets | 390M | 626M | 732M | 851M | 921M | 1.80B | 2.01B | 2.18B | 2.46B | 3.05B | 3.44B |
| Total Liabilities | 103M | 242M | 274M | 298M | 258M | 318M | 350M | 409M | 637M | 1.01B | 1.32B |
| Shareholders' Equity | 287M | 384M | 458M | 553M | 663M | 1.48B | 1.60B | 1.72B | 1.80B | 2.04B | 2.12B |
| Cash & Short-term Investments | 6.81M | 39.8M | 19.6M | 70.9M | 79.0M | 753M | 516M | 744M | 361M | 204M | 289M |
| Total Debt | 20.0M | 40.0M | 500K | 19.8M | 11.8M | 6.83M | 13.1M | 17.1M | 118M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 11.3M | 56.2M | 64.8M | 117M | 105M | 115M | 156M | 214M | 142M | 300M | - |
| Capital Expenditure | 108M | 37.6M | 35.4M | 24.3M | 53.7M | 92.1M | 132M | 106M | 234M | 520M | 599M |
| Free Cash Flow | -96.3M | 18.6M | 29.4M | 92.3M | 50.9M | 22.6M | 23.8M | 109M | -91.6M | -220M | -265M |
| Ratios | |||||||||||
| ROE | 6.5% | 15.6% | 19.3% | 21.0% | 21.9% | 10.9% | 11.4% | 12.3% | 9.1% | 11.8% | 6.1% |
| ROA | 4.8% | 9.5% | 12.1% | 13.6% | 15.7% | 8.9% | 9.1% | 9.7% | 6.7% | 7.9% | 3.8% |
| Net Profit Margin | 7.3% | 15.9% | 14.4% | 14.1% | 15.3% | 14.0% | 14.1% | 14.7% | 11.6% | 15.9% | 9.8% |
| Debt to Equity | 0.07x | 0.10x | 0.00x | 0.04x | 0.02x | 0.00x | 0.01x | 0.01x | 0.07x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hunan Warrant Pharmaceutical Co. Ltd. A dividends
- Dividend yield
- 1.02%
- Forward dividend
- 0.18 CNY
- Payout ratio
- 26.1%
- Ex-dividend date
- Jul 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 63.0M | 0.48 | 26.1% |
| 2024 | CNY 86.3M | 0.66 | 52.6% |
| 2023 | CNY 84.4M | 0.64 | 39.9% |
| 2022 | CNY 65.7M | 0.50 | 35.9% |
| 2021 | - | - | - |
| 2020 | CNY 35.2M | 0.36 | 24.2% |
| 2019 | CNY 35.2M | 0.36 | 30.3% |
| 2018 | 722K | 0.01 | 0.8% |
| 2017 | 2.08M | 0.03 | 3.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on May 29, 2025.
Who owns Hunan Warrant Pharmaceutical Co. Ltd. A
- Insiders 56.09%
- Institutions 5.95%
- Public & others 37.96%
- Shares outstanding 134M
- Free float 60.6M
Hunan Warrant Pharmaceutical Co. Ltd. A company profile
- Company name
- Hunan Warrant Pharmaceutical Co. Ltd. A
- Ticker
- 688799.SHG
- ISIN
- CNE100004P73
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,291
- Fiscal year end
- December
- Address
- Building C6-C7, Changsha, China, 410006
- Phone
- 86 731 8591 0593
- Website
- warrant.com.cn
About Hunan Warrant Pharmaceutical Co. Ltd. A
Hunan Warrant Pharmaceutical Co.,Ltd manufactures and sells pharmaceutical products in China. It offers medicines in the areas of digestive, respiratory, anti-infective, diabetes, Hypertension, calcium supplementation cardiovascular, cerebrovascular, and other fields. The company also provides APIs and Intermediates. Hunan Warrant Pharmaceutical Co.,Ltd was founded in 2001 and is based in Changsha, China.
Hunan Warrant Pharmaceutical Co. Ltd. A management
9- Mr. Ben Dong HuangChairman & GM · born 1964
- Ms. Gui Ying WuFinancial Director & Accounting Supervisor · born 1981
- Mr. Xiang GaoDirector & Deputy GM · born 1971
- Mr. Qiao QiaoSecretary to the Board · born 1991
- Ms. Dou LinDeputy General Manager · born 1976
- Mr. Zhigang ZhouDeputy General Manager · born 1980
- Mr. Jian XiaoDeputy General Manager · born 1982
- Mr. Yue TanCore Technical Staff · born 1982
- Mr. Xiaoguang ChenExecutive Officer · born 1983